Using esmolol to improve heart disease diagnosis in patients with cirrhosis and diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of esmolol-enhanced echocardiography compared to standard echocardiography in diagnosing subclinical heart issues in patients with diabetes mellitus type 2, cirrhosis, and those undergoing cancer treatments. Participants will undergo a screening period followed by baseline assessments and multiple follow-up visits over three years. The study will include blood sample collection and various health assessments to monitor cardiovascular function and biomarkers. Patients will be grouped based on their specific medical conditions for tailored evaluations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Absence of previous heart disease, defined as the absence of relevant cardiac structural alterations such as moderate or severe hypertrophy, alteration of segmental contraction, Moderate or severe valvular disease, intraventricular obstructive gradient, or old myocardial infarction.
3. Existence of an at least acceptable ultrasonic window, which allows the visualization of at least 14 of the 17 segments of the LV myocardium.
4. Sinus rhythm, with a basal heart rate greater than 50 bpm.
5. Diabetic patients with a diagnosis of Diabetes Mellitus 2 (DM2) with or without Heart Failure with Normal Ejection Fraction (HFNEF) (n = 300) will be included. Previous diagnosis of HFNEF with clinical stability at the time of inclusion (n = 200). No previous diagnosis of HFNEF (n = 100).
6. 200 patients with cirrhosis stratified by the following additional criteria will be included: Child-Pugh A class (n = 25); Child-Pugh B class (n = 75); Child-Pugh C class (with and without ascites n = 50 and n = 50, respectively).
7. 300 cancer patients will be included, divided into 3 therapeutic groups: 125 patients diagnosed with Lymphoma or Sarcoma receiving chemotherapy based on anthracyclines at high doses (≥ 240 mg / m2); 125 patients with Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer receiving chemotherapy regimen that includes trastuzumab without anthracyclines; 50 patients with hepatocarcinoma receiving treatment with Sorafenib.
8. Expected survival\> 6 months, first-diagnosis of cancer, and receiving treatment with chemotherapy that includes any of the previous schemes.
9. A control group (n = 200) without heart disease and without any of the study conditions will be included: diabetes from any cause, cancer or active cancer treatment or some degree of liver disease.

Exclusion Criteria:

1. Contraindication for the administration of esmolol (according to technical data sheet): Hypersensitivity to esmolol hydrochloride; Severe sinus bradycardia (HR \<50 bpm); 2nd or 3rd degree atrioventricular block without pacemaker; Cardiogenic shock, severe hypotension, or decompensated heart failure; Untreated pheochromocytoma; Acute asthmatic attack; Concomitant intravenous administration or within the first 48 hours after verapamil.
2. Treatment with beta-blocker drugs (oral, topical or intravenous) in the last 7 days before the study.
3. History of ventricular or supraventricular arrhythmias that prevent the safe withdrawal of antiarrhythmic or braking treatment before the administration of esmolol.
4. History of previous high-grade atrioventricular (AV) conduction disorder in non-pacemaker patients.
5. Severe asthma with bronchial hyperresponsiveness.
6. Patients with acute infection.
7. Participants in other clinical trials in the 30 days prior to the start of the study.
8. Pregnant women, or who plan to be, and women during breastfeeding.
9. Patients with limitation to follow the protocol for any reason.
10. Diagnosis of Diabetes Mellitus (DM) of any type other than type 2 \[type 1, Latent Autoimmune Diabetes in Adults (LADA), Maturity-Onset Diabetes of the Young (MODY), New Onset Diabetes After Transplant (NODAT), etc.\]
11. Patients in New York Heart Association (NYHA) functional class IV or with advanced heart failure.
12. Treatment with an oral beta-blocker at the time of the examination that cannot be safely temporarily suspended 72 hours before the test.
13. Active evidence of Hepatitis B Virus (HBV) or Hepatitis B Virus (HCV) infection.
14. Personal history of previous cancer requiring systemic treatment (excludes skin or localized cancers treated locally surgically).
15. Previous exposure to systemic antitumor treatment or radiotherapy on the thoracic region.

Where it's running

• Hospital Universitari Vall d'Hebron
  Barcelona, Barcelona, Spain Recruiting
• Hospital General Universitario Gregorio Marañón
  Madrid, Madrid, Spain Recruiting
• Hospital Universitario La Paz
  Madrid, Madrid, Spain Recruiting
• Hospital Clínico Universitario de Salamanca
  Salamanca, Salamanca, Spain Recruiting
• Hospital Clínic de Barcelona
  Barcelona, Barcelona, Spain Not yet recruiting
• Hospital Universitari i Politècnic La Fe
  Valencia, Valencia, Spain Not yet recruiting

Study contacts

• Principal investigator: Javier Bermejo Thomas, MD, PhD — Hospital Universitario Gregorio Marañón
• Study coordinator: Tania Luis García, BS
• Email: tanialuisgarcia@cibercv.es
• Phone: +34 917996034

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis

  This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.

  Recruiting University Medical Center Ho Chi Minh City (UMC) · Ho Chi Minh City · NCT07918378

• Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing

  A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jang XI · NCT07881588

• EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis

  This trial tests whether using endoscopic ultrasound to guide coils plus glue works better than glue alone for stopping bleeding from gastric varices in adults with cirrhosis.

  Recruiting Medanta, The Medicity, India · Orlando, Florida and 1 other locations · NCT07855913

• DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman

  A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.

  Recruiting Oman Ministry of Health · Muscat · NCT07815275

• Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes

  This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.

  Recruiting Fidam Rdc · Bad Mergentheim, Baden-Wurttemberg · NCT07814508

• SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes

  This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.

  Recruiting Maxima Medical Center · Eindhoven, North Brabant · NCT07812623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.